Acta Med. Okayama, 2017
Vol. 71, No. 1, pp. 11‑17
CopyrightⒸ 2017 by Okayama University Medical School.
Original Article
http://escholarship.lib.okayama-u.ac.jp/amo/
Frequency of Exacerbations and Hospitalizations
in COPD Patients Who Continue to Smoke
Serap Argun Barisa*, Tugba Onyilmazb, Ilknur Basyigita, Hasim Boyacia, and Fusun Yildiza
a
Department of Pulmonary Diseases, Kocaeli University School of Medicine, Kocaeli 41380, Turkey,
b
Department of Pulmonary Diseases, Private Konak Hospital, Kocaeli 41100, Turkey
We evaluated the frequency of exacerbations and hospitalizations in chronic obstructive pulmonary disease
(COPD) patients who continue to smoke.: We retrospectively analyzed the medical records of the COPD
patients treated in Chest Diseases Clinic of Kocaeli University School of Medicine in 2007-2013. Their demographic characteristics, smoking status (non-smoker, current smoker, ex-smoker), Charlson Comorbidity
Index (CCI), and history of COPD exacerbation and hospitalizations were evaluated. The cases of 120 patients
(11 females, 9.2%; 109 males, 90.8%) were analyzed. Sixteen (13.3%) of the patients were current smokers,
and 104 patients were ex-smokers (n = 99) or non-smokers (n = 5). The mean age was 69.7 ± 7.9 years in the
ex-smokers and 62.94 ± 6.8 years in the current smokers. There were no significant differences between the current and ex-smokers regarding smoking history, FEV1 value, frequencies of exacerbations and hospitalization
per year, or duration of follow-up. The initial stage of the COPD and the frequency of exacerbations were significantly correlated (p = 0.003). The CCI values were significantly higher in the ex-smokers compared to current
smokers (p = 0.02). A correlation analysis of age, hospitalization and CCI revealed that age was significantly
correlated with the hospitalization rate (p = 0.02). Older age and the presence of comorbidities in ex-smokers
might explain the similar rates of exacerbation and hospitalization between these current and ex-smokers.
Key words: COPD, exacerbation, hospitalization, smoking, age
C
hronic obstructive pulmonary disease (COPD) is
treatable and preventable chronic disease characterized by persistent airflow limitation that is usually
progressive and associated with an increased inflammatory response to noxious particles and gases [1]. An
interaction between genetic susceptibility and environmental exposure has a role in the development of
COPD [2]. Cigarette smoking is the most important
etiologic factor. It is reported that nearly 50% of smokers will develop COPD [3]. The reduction and elimination of exposure to risk factors have great importance
for the prevention of COPD progression.
Received March 9, 2016 ; accepted July 27, 2016.
Corresponding author. Phone : +90-262-3037211; Fax : +90-262-3037003
E-mail : serapargun2002@yahoo.com (Baris SA)
*
The exacerbation of COPD is defined as an acute
event characterized by a worsening of respiratory symptoms that is beyond normal day-to-day variations and
leads to a change in medication [1]. Exacerbations are
an important cause of mortality and morbidity in COPD
patients [4-6]. The frequency of exacerbations varies
from patient to patient, and frequent exacerbations
have a negative impact on an individual’s quality of life
[7]. The main determinants of frequent exacerbations
(i.e., ≥ 2 per year) are prior treated exacerbations and an
increase in airflow limitation.
Clinical failure after the treatment of a COPD exacerbation is common. Impaired lung function, dyspnea
Conflict of Interest Disclosures: No potential conflict of interest relevant
to this article was reported.
12
Baris et al.
Acta Med. Okayama Vol. 71, No. 1
and active smoking have been associated with clinical
failure [6]. However, Yip et al. reported that the active
smoking rate of COPD patients was similar among
patients with a single hospital admission versus those
with multiple hospital admissions [8], and Alcazar et al.
indicated that they found no significant difference in the
active smoking rate based on previous hospitalizations
[9].
Smoking is known as risk factor for the development of COPD, and in recent guidelines smoking cessation is emphasized as a key intervention for all COPD
patients who continue to smoke [1]. However, the
similarities and differences in the clinical presentation
of COPD patients according to their smoking status
have not been fully described [10]. The complete elucidation of a risk factor is the first step in the management and early prevention strategies in COPD patients,
as this may reduce the frequency of exacerbations and
hospitalizations. We conducted the present study to
evaluate the role of active smoking in the frequency of
exacerbations and hospitalizations among patients with
COPD.
Patients and Methods
We retrospectively analyzed the medical records of
the consecutive COPD patients who were treated in
Chest Diseases Clinic of Kocaeli University School of
Medicine in Turkey in the years 2007-2013. We determined each patient’s demographic characteristics,
smoking history, Charlson Comorbidity Index (CCI)
score, initial forced expiratory volume in 1 sec (FEV1)
value, stage of COPD, duration of follow-up, and history of exacerbations and hospitalizations. Generally,
hospitalization due to respiratory symptoms of COPD is
regarded as a severe exacerbation. We therefore included
the number of hospitalizations in the exacerbation
number. The presence of a post-bronchodilator FEV1/
forced vital capacity (FVC) value < 0.70 confirmed the
presence of airflow limitation according to the Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
guideline [1].
Smoking history.
We defined smoking history of
the patients according to consumption of cigarette per
day and number of year by self-reports of patients on a
questionnaire [Pack years = (Number of cigarettes per
day/20) × Number of years]. The consumption of other
tobacco products were not considered.
Non-smoker: A patient who had never smoked on a
regular basis.
Ex-smoker: A regular smoker who had a smoking history at least 10 pack years and who had stopped smoking > 6 months before admission.
Current smoker: A patient with a smoking history of at
least 10 pack years and who had smoked regularly
within 6 months.
Severity of COPD. We classified the severity of
the patients’ COPD according to their post-bronchodilator FEV1 values, as follows:
GOLD 1: Mild FEV1, ≥ 80% of the predicted value
GOLD 2: Moderate, 50% ≤ FEV1 < 80% predicted
GOLD 3: Severe, 30% ≤ FEV1 < 50% predicted
GOLD 4: Very severe, FEV1 < 30% predicted
Exacerbation.
We defined ‘exacerbation of
COPD’ as an acute event characterized by a worsening
of the patient’s respiratory symptoms that was beyond
normal day-to-day variations and led to a change in
medication [1]. The number of exacerbations within the
prior 12 months for each COPD patient was determined.
The Charlson Comorbidity Index (CCI). We
evaluated the patients’ comorbidities by using the predefined list of medical conditions that is used to calculate the CCI (both unadjusted and age-adjusted) [11].
The CCI encompasses 19 medical conditions weighted
1-6, with total scores ranging from 0 to 37. From the
weighted conditions, a sum score can be tallied to yield
the total comorbidity score. The CCI can be further
adapted to account for increasing age. In the validation
phase of the CCI in the present study, age was found to
be an independent risk factor for death from a comorbid condition. To account for the effects of increasing
age, one point can be added to the CCI score for each
decade of life over the age of 50 [12].
A CCI score of 1 indicates the absence of comorbidities other than COPD. Patients with a CCI score of 2
were classified as having low comorbidity, and those
with scores ≥ 3 were classified as having high comorbidity.
Exclusion criteria.
Patients with other lung diseases such as tuberculosis, bronchiectasis and interstitial lung disease were excluded from the present analyses, as were patients who had an airflow limitation due
to abnormalities in the large airways.
Statistical analysis.
We used the Statistical
Package for Social Sciences (SPSS 16.0) program for the
February 2017
Smoking History and COPD Exacerbations
statistical analyses of the data. Categorical variables
were recorded as percentages, and numeric variables
were recorded as mean and standard deviation (SD).
Compliance with the normal distribution of data was
evaluated by Shapiro-Wilk test. The chi-square test was
used for comparing non-parametric variables. A
p-value < 0.05 was considered significant.
Results
The cases of a total of 120 patients (11 females,
9.2%; 109 males, 90.8%) were analyzed. The mean
duration of follow-up was 3.2 ± 1.7 years. Sixteen
(13.3%) of the patients were current smokers; 5 (4.2%)
were non-smokers, and 99 (82.5%) were ex-smokers.
The percentages of these three categories are illustrated
in Fig. 1.
The patients’ characteristics and frequency of exacerbations and hospitalizations according to the patients’
smoking status are summarized in Table 1. The mean
age of the ex-smokers was 69.7 ± 7.9 years; that of the
current smokers was 62.94 ± 6.8 years, and that of the
non-smokers was 66.2 ± 6.8 years. The mean ages of
current and ex-smokers were significantly different
(p = 0.005). There were no significant differences
between the current and ex-smokers in smoking packyears, FEV1 values, frequency of exacerbations, frequency of hospitalizations in the prior 12 months, or
Table 1
13
the duration of follow-up. Stage 4 COPD was noted in
7 (7.1%) of the ex-smokers but in none of the current
smokers.
Significant correlations were revealed between the
initial stage of COPD and the frequency of the exacerbations (p = 0.003, initial stage of COPD and the frequency of exacerbations peryear (p = 0.001), and initial
stage of COPD and the frequency of hospitalizations per
year, ︲(p = 0.000)) (Fig. 2).
The CCI scores and age-adjusted CCI scores were
significantly higher in the ex-smokers compared to the
current smokers (p = 0.02 and p = 0.002, respectively;
Table 1, Fig. 3A, B).
In a correlation analysis of the factors of age, hospi4.2
13.3
82.5
Non smoker
Fig. 1
Current smoker
Ex smoker
The 120 COPD patientsʼ smoking status.
The characteristics of the 120 COPD patients according to smoking status
Age (yrs)
Male/female (n, %)
Smoking package of years
Pack years = (Number of cigarettes per day/20) X
Number of years
No. of exacerbations
Duration of follow-up (months; mean)
No. of hospitalizations
No. of hospitalizations during the prior 12 months
CCI
CCI (age-adjusted)
FEV1 initial (l)
FEV1 initial %
Non-smokers
(n = 5)
Current Smokers
(n = 16)
Ex-smokers
(n = 99)
66.2 ± 6.8
3 (60%)/2 (40%)
62.94 ± 6.8a
14 (87.5%)/2 (12.5%)
69.7 ± 7.9a
92 (92.9%)/7 (7.1%)
0
43.4 ± 25.7
47.2 ± 27.7
0.6
1.8 ± 1.5
3.2 ± 1.1
0.2 ± 0.4
0.1 ± 0.2
1.4 ± 0.5
4.4 ± 1.1
1.73 ± 0.5
68.6 ± 16.6
1.5 ± 2.1
2.9 ± 1.7
0.69 ± 1.4
0.23 ± 0.5
1.25 ± 0.4b
4.0 ± 0.96c
1.71 ± 0.4
56.8 ± 12.2
1.8 ± 2.2
3.2 ± 1.7
0.79 ± 1.8
0.21 ± 0.4
1.7 ± 0.8b
4.96 ± 1.2c
1.68 ± 0.7
57.39 ± 19.4
0.6
0.6
0.8
0.9
0.02
0.002
0.8
0.9
p
0.005
CCI, Charlson Comorbidity Index; FEV1, forced expiratory volume in 1 sec.
Comparison of groups: Statistically significant differences (p < 0.05) were summarized.
Age, aCurrent smokers and ex-smokers, p = 0.005; CCI, bCurrent smokers and ex-smokers, p = 0.02; CCI age adjusted, cCurrent smokers
and ex-smokers, p = 0.002.
14
Baris et al.
Acta Med. Okayama Vol. 71, No. 1
68.8
70
60
60
52.5
50
GOLD Stage 1
40
30
20
31.2
GOLD Stage 3
20
20
GOLD Stage 4
11.1
7.1
10
0
GOLD Stage 2
29.3
Non smoker
Current smoker
Ex smoker
Fig. 2
The distribution of disease severity according to smoking
status (%). See the Patients and Methods section for the explanation of GOLD stages.
48
50
40
33
Charlson 1
30
Charlson 3
12
10
0
Charlson 2
18
20
3
4
2
Non smoker
Current smoke
Ex smoker
29
30
25
25
24
3
20
4
15
10
10
5
0
6
1
2
1 1
Non smoker
5
11
5
6
7
4
1
Current smoker
Ex smoker
Fig. 3
A: The distribution of CCI scores according to smoking
status (n). CCI score of 1 = absence of comorbidity other than
COPD. CCI score of 2 = low comorbidity (COPD + 1 comorbidity).
CCI score of 3 = high comorbidity (COPD + ≥ 2 comorbidities).
B: Age-adjusted CCI scores according to smoking habits (n).
talization rate and CCI scores, we found that age was
significantly correlated with the hospitalization rate
(p = 0.02). There were 90 hospitalizations among the
total patient series during the study period, and 80% of
these episodes occurred in patients > 65 years old. No
correlation was found between CCI scores and the hospitalization rate, but there were 63 patients (52.5%)
who had no comorbid condition other than COPD. We
also noted that there were 50 hospitalizations in the
remaining 57 patients who had higher CCI scores.
Discussion
Our retrospective analysis of 120 patients with
COPD revealed that the rate of active smoking was low
in this patient series, and it was lower than those of
previous studies as summarized below. We found no
significant difference in the numbers of exacerbation
episodes or hospitalizations between the current smokers and ex-smokers.
COPD is one of the most important causes of mortality and morbidity throughout the world. In older
individuals in the United States, it is among the 10 most
important diseases causing hospitalizations and death,
with a prevalence that is increasing day by day [13].
COPD is more common in men than women due to
males’ higher rates of smoking and occupational exposure. However, the increase in cigarette smoking
among women and their increasing presence in dangerous work environments have led to an increase in the
prevalence of COPD in women [14]. There was also a
male dominance in our study; only 11% of the patients
were female.
Some of the risk factors of COPD are well known:smoking, occupational exposure, air pollution, airway
hyper-responsiveness, and genetic variations [15]. The
assessment of risk factors is important in the management of COPD patients, and smoking is the most
important etiologic factor. However, the exposure to
passive smoking and biomass fuel used for heating are
discriminative for women among non-smoker COPD
patients [16]. In our study, 4.2% of the patients were
non-smokers whereas 95.8% of the patients had a
smoking history (13.3% of the patients were current
smokers, plus 82.5% of the patients were ex-smokers).
Forty percent of the non-smoker patients were female
and they had biomass exposure. Although smoking
cessation is the first step in the management of COPD,
active smoking rates are still high in COPD patients. In
a previous study, many patients continued to smoke
after the diagnosis of COPD (16.8%) or lung cancer
(15.1%) [16]. The active smoking prevalence varies in
February 2017
different working groups. In the ESFERA study of
COPD patients conducted in Spain, the active smoking
rate was 19.3% [6]. An evaluation of the hospitalizations due to COPD exacerbation revealed active smoking in 33% of the patients [16]. The active smoking rate
in the present study (13.3%) is relatively low. In our
department, we have a separate outpatient smoking
cessation clinic and an outpatient COPD clinic designed
to treat these two groups of individuals separately. The
major goals of our COPD management policy are the
education of the patients about both COPD and smoking cessation. This may explain the lower rate of current
smokers in our study population.
It has been reported that respiratory symptoms, the
annual decrease of FEV1 values and mortality rates are
higher in smokers than nonsmokers [1]. The most
effective strategy to prevent declining lung function
among COPD patients is smoking cessation [17].
Smoking cessation should be considered for all COPD
patients regardless of the level of disease severity [1].
Exacerbations of COPD are the most frequent cause
of morbidity, hospital admissions and mortality in
COPD patients [17]. The early detection and effective
treatment of exacerbations are key factors that may
reduce the likelihood of hospital admissions and prevent re-admissions [18]. However, clinical failure after
the treatment of COPD is common, and active smoking, impaired lung function, and severe dyspnea are
associated with clinical failure [6]. Re-admissions are
associated with the degree of lung function impairment
(as shown by GOLD grades), lower FEV1 and the frequency of previous exacerbations [19-21]. As in prior
studies, our present analysis showed that the initial
stage of the disease (according to GOLD stage) and the
frequency of exacerbations are correlated (p = 0.003).
However, there were no significant differences in FEV1
values, the frequency of exacerbations or the number of
hospitalizations in the prior 12 months between the
current smokers and ex-smokers in our series. We suspect that the older age and presence of comorbidities in
the ex-smoker group and the absence of stage 4 disease
in the current smoker group might explain the similar
rates of exacerbation and hospitalization between the
current and ex-smokers.
COPD is a chronic, systemic disease with comorbidities that affect respiratory symptoms, worsen the
prognosis, and increase the exacerbation frequency and
mortality [22 , 23]. There is a causal relationship between
Smoking History and COPD Exacerbations
15
COPD and comorbidities that influences the clinical
course of the disease [24]. The severity and prognosis of
exacerbation is best predicted by the presence or
absence of significant comorbid conditions [17].
Several reports suggest that cardiovascular disease is
associated with the exacerbation of COPD [25 , 26].
The CCI, which is a predefined list of medical conditions used to calculate a comorbidity score, has good
reliability and an excellent correlation with mortality,
and it is easily modified, particularly to account for the
effect of age. The CCI is preferred for its ease of use,
short rating time, extractability from other indices, and
widespread use [10]. The CCI scores of the present
study’s ex-smokers were significantly higher compared
to those of the current smokers. We speculate that the
higher comorbidity scores in the ex-smokers compared
to the current smokers could be explained by the need
to quit smoking based on the fear of a decreased quality
of life related to intense comorbidities.
Our correlation analysis regarding patient age, hospitalization and CCI revealed that age is correlated with
the rate of hospitalizations, which is not unexpected
since 80% of the hospitalizations occurred in patients
> 65 years old. However, there was no correlation
between CCI scores and hospitalization. Nearly half of
the study group (47.5%) had at least one comorbid condition other than COPD, and patients with high CCI
scores accounted for 55.6% of the hospitalizations.
These findings suggest that the CCI is an important factor for hospitalization in COPD patients. We suspect
that the limited number of patients with multiple
comorbid conditions in this study might be responsible
for the nonsignificant relationship between CCI scores
and hospitalization.
Limitations of the study. There are several limitations to our study that should be considered. First, it
was a retrospective investigation, and the data collection was based on medical records. Second, the number of current smokers was low compared to that of
ex-smokers. Third, there was no current smoker in the
stage 1 or stage 4 COPD groups. It is possible that stage
4 COPD patients are unable to smoke because of their
disease severity, and we suspect that these patients ‘stop
smoking’ simply because they cannot smoke. This may
explain why there was no current smoker in the stage 4
COPD group. Since there were no current smokers in
the stage 1 or 4 COPD groups, our assessment regarding smoking history concerned mostly stage 2 and 3
16
Baris et al.
Acta Med. Okayama Vol. 71, No. 1
patients. This nonhomogeneous distribution of smokers among the patient groups may have affected our
results concerning the relationship between current
smoking and the exacerbation and hospitalization rates
of COPD patients. Future studies are needed to determine whether our results are also applicable for all
stages of COPD patients.
Fourth, the goals of COPD assessment are to determine the severity of the disease, its impact on a patient’s
health status and the risk of future events such as exacerbation, hospitalization and death. However, due to
the retrospective nature of this study, we could not
determine the patients’ health status by using, for
example, the modified Medical Research Council
(mMRC) Questionnaire or the COPD assessment test
(CAT), and we could not evaluate the new classification of COPD. The severity of the patients’ COPD was
thus classified by using only post-bronchodilator FEV1
values. Lastly, the gender distribution among our
patient groups was not homogenous since smoking was
more prevalent in male than females in our country.
It is accepted that assessments of COPD require a
combination of parameters including pulmonary functions, exacerbation history, severity of symptoms and
comorbid conditions. Our findings suggest that the
implementation of a questionnaire inquiring about
comorbidities (such as the CCI) in a patient’s follow-up
might be helpful to predict the hospitalization and exacerbation risks in COPD patients, since the presence of
comorbid conditions was shown to be a more important
factor in exacerbations than current smoking.
In conclusion, the current smoking rate in our present series of 120 COPD patients was lower than those of
previous studies. We observed no significant difference
in the numbers of exacerbations or hospitalizations
between the current smokers and ex-smokers. The older
age and the presence of comorbidities in the ex-smokers
group might explain the similar rates of exacerbations
and hospitalizations between the current and former
smokers. Further prospective trials including more
patients both in ex-smoker and current smoker arms are
needed to clarify the relationships among exacerbation,
smoking status and comorbidities in COPD patients.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
References
1.
Sen E, Guclu SZ, Kibar I, Ocal U, Yilmaz V, Celik O, Cimen F,
Topcu F, Orhun M, Tereci H, Konya A, Ar I and Saryal S:
16.
Adherence to GOLD guideline treatment recommendations among
pulmonologists in Turkey. Int J Chron Obstruct Pulmon Dis (2015)
10: 2657-2663.
Hooper R, Burney P, Vollmer WM, McBurnie MA, Gislason T,
Tan WC, Jithoo A, Kocabas A, Welte T and Buist AS: Risk factors for COPD spirometrically defined from the lower limit of normal
in the BOLD Project. Eur Respir J (2012) 39: 1343-1353.
Lundback B, Lindberg A, Lindström M, Rönmark E, Jonsson AC,
Jönsson E, Larsson LG, Andersson S, Sandström T and Larsson K;
Obstructive Lung Disease in Northern Sweden Studies: Obstructive
Lung Disease in Northern Sweden S: Not 15 but 50% of smokers
develop COPD?-Report from the Obstructive Lung Disease in
Northern Sweden Studies. Respir Med (2003) 97: 115-122.
Celli BR and Mac Nee W: ATS/ERS Task Force. Standards for
the diagnosis and care of patients with COPD: a summary of the
ATS/ERS position paper. Eur Respir J (2004) 23: 932-946.
Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C,
Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M,
Stockley RA, Sin DD and Rodriguez-Roisin R: Global strategy for
the diagnosis, management, and prevention of chronic obstructive
pulmonary disease: GOLD executive summary. Am J Respir Crit
Care Med (2013) 187: 347-365.
Miravitlles M, Izquierdo I, Herrejón A, Torres JV, Baró E and
Borja J; ESFERA investigators: COPD severity score as a predictor of failure in exacerbations of COPD. The ESFERA study.
Respir Med (2011) 105: 740-747.
Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ
and Wedzicha J: Effect of exacerbation on quality of life in
patients with chronic obstructive pulmonary disease. Am J Respir
Crit Care Med (1998) 157: 1418-1422.
Yip NH, Yuen G, Lazar EJ, Regan BK, Brinson MD, Taylor B,
George L, Karbowitz SR, Stumacher R, Schluger NW and
Thomashow BM: Analysis of hospitalizations for COPD exacerbation: opportunities for improving care. COPD (2010) 7: 85-92.
Alcázar B, García-Polo C, Herrejón A, Ruiz LA, de Miguel J, Ros
JA, García-Sidro P, Conde GT, López-Campos JL, Martínez C,
Costán J, Bonnin M, Mayoralas S and Miravitlles M: Factors
Associated With Hospital Admission for Exacerbation of Chronic
Obstructive Pulmonary Disease. Arch Bronconeumol (2012) 48:
70-76. doi:10.1016/j.arbres.2011.10.009. Epub 2011 Dec 21.
Zhang J, Lin XF and Bai CX: Comparison of clinical features
between non-smokers with COPD and smokers with COPD: a retrospective observational study. Int J Chron Obstruct Pulmon Dis
(2014) 9: 57-63.
Charlson M, Szatrowski TP, Peterson J and Gold J: Validation of
combined comorbidity index. J Clin Epidemiol (1994) 47: 12451251.
Hall WH, Ramachandran R, Narayan S, Jani AB and Vijayakumar
S: An electronic application for rapidly calculating Charlson
comorbidity score. BMC Cancer (2004) 20: 4: 94.
Mannino DM: COPD. Epidemiology, prevalence, morbidity and
mortality, and disease heterogenity. Chest (2002) 121: 121S-126S.
Caracta CF: Gender differences in pulmonary disease. Mt Sinai J
Med (2003) 70: 215-224.
Bourbeau J, Tan WC, Benedetti A, Aaron SD, Chapman KR,
Coxson HO, Cowie R, Fitzgerald M, Goldstein R, Hernandez P,
Leipsic J, Maltais F, Marciniuk D, OʼDonnell D, Sin DD and
Cancold Study Group: Fulfilling the need for longitudinal observational studies in COPD. COPD (2014) 11: 125-132.
Vaidya V, Hufstader-Gabriel M, Gangan N, Shah S and Bechtol R:
Utilization of smoking-cessation pharmacotherapy among chronic
February 2017
17.
18.
19.
20.
21.
obstructive pulmonary disease (COPD) and lung cancer patients.
Curr Med Res & Opin (2014) 30: 1043-1050.
Miravitlles M, Guerrero T, Mayordomo C, Sánchez-Agudo L,
Nicolau F and Segú JL: Factors Associated with Increased Risk of
Exacerbation and Hospital Admission in a Cohort of Ambulatory
COPD Patients: A Multiple Logistic Regression Analysis. Respiration (2000) 67: 495-501.
Suh ES, Mandal S and Hart N: Admission prevention in COPD:
non-pharmacological management. BMC Medicine (2013) 11: 247.
Gudmundsson G, Gislason T, Janson C, Lindberg E, Hallin R,
Ulrik CS, Brøndum E, Nieminen MM, Aine T and Bakke P: Risk
factors for rehospitalisation in COPD: role of health status, anxiety and depression. Eur Respir J (2005) 26: 414-419.
Liu D, Peng SH, Zhang J, Bai SH, Liu HX and Qu JM: Prediction
of short term re-exacerbation in patients with acute exacerbation of
chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon
Dis (2015) 10: 1265-1273.
Ozyilmaz E, Kokturk N, Teksut G and Tatlicioglu T: Unsuspected
risk factors of frequent exacerbations requiring hospital admission
in chronic obstructive pulmonary disease. Int J Clin Pract (2013)
Smoking History and COPD Exacerbations
22.
23.
24.
25.
26
17
67: 691-697.
Warwick E, Scourfield A and Quint J: Systemic manifestations of
chronic obstructive pulmonary disease. Br J Hosp Med (Lond)
(2015) 76 (Suppl): 324-329.
Barnes PJ and Celli BR: Systemic manifestations and comorbidities of COPD. Eur Respir J (2009) 33: 1165-1185.
Decramer M, Rennard S, Troosters T, Mapel DW, Giardino N,
Mannino D, Wouters E, Sethi S and Cooper CB: COPD as a
Lung Disease with Systemic Consequences-Clinical Impact,
Mechanisms, and Potential for Early Intervention. COPD (2008)
5: 235-256.
Pavasini R, dʼAscenzo F, Campo G, Biscaglia S, Ferri A, Contoli
M, Papi A, Ceconi C and Ferrari R: Cardiac troponin elevation
predicts all-cause mortality in patients with acute exacerbation of
chronic obstructive pulmonary disease: Systematic review and
meta-analysis. Int J Cardiol (2015) 191: 187-193.
Ko FW, Chan KP, Hui DS, Goddard JR, Shaw JG, Reid DW and
Yang IA: Acute exacerbation of COPD. Respirology (2016) 21:
1152-1165.